Clinical trial
Maribavir for Prevention of CMV After Stem Cell Transplants
NCT00223925 · Shire, Industry · Completed
Key facts
| NCT number | NCT00223925 |
|---|---|
| Title | Maribavir for Prevention of CMV After Stem Cell Transplants |
| Official title | A Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Assess the Safety, Tolerability, and Prophylactic Anti-cytomegalovirus Activity of Maribavir in Recipients of Allogeneic Stem Cell Transplants |
| Lead sponsor | Shire, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cytomegalovirus Infection |
| Intervention type | Drug |
| Interventions | Maribavir, Placebo |
| Enrollment | 111 |
| Start date | Oct 28, 2004 |
| Primary completion | Apr 5, 2006 |
| Completion | Apr 5, 2006 |
| First posted | Sep 22, 2005 |
| Last update posted | May 13, 2021 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: